Tandem Diabetes Care, a medical device company specializing in products for individuals with insulin-dependent diabetes, recently received a decreased price target from Jefferies Financial Group. In a report released on October 2, 2023, the analysts lowered the price target from $47.00 to $45.00.
This adjustment reflects a potential upside of 116.66% from the current stock price. Despite this revised projection, Jefferies Financial Group maintains its “buy” rating on Tandem Diabetes Care’s stock.
https://beststocks.com/tandem-diabetes-care-faces-challenges-but-drives-i/
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.